Endothelin Receptor Subtype A Blockade Selectively Reduces Pulmonary Pressure After Cardiopulmonary Bypass
Overview
Authors
Affiliations
Background: The bioactive peptide endothelin-1 is elevated during and after cardiopulmonary bypass and exerts cardiovascular effects through its 2 receptor subtypes, endothelin-1A and endothelin-1B. Increased endothelin-1A receptor stimulation after cardiopulmonary bypass can cause increased pulmonary vascular resistance and modulate myocardial contractility. However, whether and to what degree selective endothelin-1A blockade influences these parameters in the postbypass setting is not completely understood.
Objectives: Our objective was to measure left ventricular function and hemodynamics in a porcine model of cardiopulmonary bypass after selective blockade of endothelin-1A.
Methods: Adult pigs (n = 23) underwent 90 minutes of cardiopulmonary bypass and were randomized 30 minutes after bypass to receive a selective endothelin-1A antagonist (TBC 11251, 10 mg/kg; n = 13) or saline vehicle (n = 10).
Results: After bypass and before randomization, pulmonary vascular resistance rose nearly 4-fold, and left ventricular preload recruitable stroke work fell to one third of baseline values (both P <.05). In the vehicle group pulmonary vascular resistance continued to rise, and preload recruitable stroke work remained reduced. However, after endothelin-1A blockade, the rise in pulmonary vascular resistance was significantly blunted compared with that in the vehicle group. Moreover, the reduction in pulmonary vascular resistance with endothelin-1A blockade was achieved without a significant change in systemic perfusion pressures.
Conclusions: The present study demonstrated that increased activity of the endothelin-1A receptor likely contributes to alterations in pulmonary vascular resistance in the postbypass setting. Selective endothelin-1A blockade may provide a means to selectively decrease pulmonary vascular resistance without significant effects on systemic hemodynamics.
Schuuring M, Boekholdt S, Windhausen A, Bouma B, Groenink M, Keijzers M Neth Heart J. 2011; 19(12):509-13.
PMID: 22086272 PMC: 3221753. DOI: 10.1007/s12471-011-0218-x.
Recent progress in treatment of pulmonary arterial hypertension due to congenital heart disease.
Schuuring M, van Riel A, Bouma B, Mulder B Neth Heart J. 2011; 19(12):495-7.
PMID: 22081363 PMC: 3221748. DOI: 10.1007/s12471-011-0220-3.
Schuuring M, Bolmers P, Mulder B, de Bruin-Bon R, Koolbergen D, Hazekamp M Int J Cardiovasc Imaging. 2011; 28(4):755-62.
PMID: 21637982 PMC: 3360845. DOI: 10.1007/s10554-011-9892-4.
Toole J, Ikonomidis J, Szeto W, Zellner J, Mulcahy J, Deardorff R J Thorac Cardiovasc Surg. 2010; 139(3):646-54.
PMID: 20074751 PMC: 2827656. DOI: 10.1016/j.jtcvs.2009.11.046.
Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation.
Ford R, Mains I, Hilton E, Reeves S, Stroud R, Crawford Jr F Ann Thorac Surg. 2008; 86(5):1576-83.
PMID: 19049753 PMC: 2671963. DOI: 10.1016/j.athoracsur.2008.06.076.